Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy

Neurology

Volumn 54, Issue 9, 2000, Pages 1877-

  Yoshita, Mitsuhiro ^a  

^a NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HEART SCINTISCANNING; LETTER; PARKINSON DISEASE; PRIORITY JOURNAL; SHY DRAGER SYNDROME; HEART MUSCLE; HUMAN; METABOLISM; NOTE; PREDICTION AND FORECASTING; SCINTISCANNING;

(3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT;

3-IODOBENZYLGUANIDINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SYSTEM ATROPHY; MYOCARDIUM; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS;

EID: 85047278356     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.54.9.1877-a     Document Type: Letter

References (12)

1. 123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999; 53:1020-1025.
2. Yoshita M, Hayashi M, Hirai S. Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Clin Neurol 1997; 37:476-482.
3. Yoshita M, Hayashi M, Hirai S. Differential diagnosis of akinetic rigid syndromes using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. Mov Disord 1997; 12(suppl 1):54. Abstract.
4. Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155:60-67.
5. Sisson JC, Shapiro B, Meyers I, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987; 28:1625-1636.
6. 123I-meta-iodobenzyl guanidine in Parkinson’s disease. Nucl Med Commun 1998; 19:137-142.
7. 123I]iodobenzylguanidine in Parkinson’s disease and autonomic failure. Acta Neurol Scand 1998; 97:307-314.
8. 123I-MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac denervation and diagnostic value. J Nucl Med 1999; 40:371-375.
9. Brefel-Courbon C, Courbon F, Thalamas C, et al. Myocardial meta-[123I]iodobenzylguanidine (MIBG) uptake is different in Parkinson’s disease and multiple system atrophy with autonomic failure. Clin Autonom Res 1999; 9:285.
10. Sobue I, Senda Y, Hirayama K, et al. Clinical pharmacological evaluation of l -threo-3,4-dihydroxyphenylserine (l -DOPS) in Shy-Drager’s syndrome and related diseases. A nation-wide double-blind comparative study. Jpn J Clin Exp Med 1987; 141:353-378.
11. Gasiner B, Roisin MP, Scherman D, et al. Uptake of metaiodobenzylguanidine by bovine chromaffin granules membranes. Mol Pharmacol 1985; 29:275-280.
12. Solanki KK, Bomanji J, Moyes J, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13:513-521.